dr. ledermann on rationale for ariel3 trial in ovarian cancer
Published 5 years ago • 100 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
1:19
dr. ledermann on phase iii ariel3 results in ovarian cancer
-
1:02
dr. ledermann on the results of the ariel3 trial in ovarian cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
5:04
rucaparib and ariel3 – positive results from the phase 3 trial in ovarian cancer patients
-
1:14
dr. gonzalez-martin on rationale for phase iii prima trial in advanced ovarian cancer
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
-
1:42
dr. ledermann on rucaparib maintenance in ovarian cancer
-
7:10
jonathan a ledermann – maintenance treatment for recurrent ovarian carcinoma
-
1:57
dr. ledermann on parp inhibitors in maintenance therapy for ovarian cancer
-
1:42
phase iii results for rucaparib in ovarian cancer
-
1:14
dr. ledermann on the treatment landscape for rare gynecologic cancers
-
6:12
rucaparib for recurrent ovarian cancer
-
1:00
dr. ledermann discusses patient selection in ovarian cancer
-
2:09
rucaparib maintenance for recurrent ovarian carcinoma
-
9:31
ariel3: rucaparib as maintenance therapy in recurrent ovarian cancer patients
-
1:20
dr. ledermann discusses olaparib in ovarian cancer
-
2:11
dr. mirza on the rationale for the avanova trial in recurrent ovarian cancer
-
3:07
rucaparib maintenance and monotherapy for ovarian cancer: trial updates
-
2:15
toxicities associated with rucaparib for the treatment of ovarian cancer